Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Moehler

Showing results (101-110 of 218) with videos related to

Pageof 22
Sort By:
Oncology Reports|November 8, 2006
Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced diseaseThomas Wehler, Felix Wolfert, Carl C Schimanski, et al.
BMC Cancer|January 13, 2019
Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker programMarkus Moehler, Annett Maderer, Anne Ehrlich, et al.
BMC Cancer|January 16, 2020
Young-onset gastric cancer and Epstein-Barr Virus (EBV) - a major player in the pathogenesis?Assaf Moore, Elad Hikri, Tal Goshen-Lago, et al.
International Journal of Colorectal Disease|September 18, 2012
Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapyThomas C Wehler, Swaantje Hamdi, Annett Maderer, et al.
BMC Cancer|February 12, 2013
Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junctionMarkus Moehler, Ines Gockel, Hans-Peter Roessler, et al.
Acta Oncologica (Stockholm, Sweden)|August 6, 2021
CXCR4 and hif-1α as prognostic molecular markers for stage 3 colon cancer patients: post hoc analysis of the randomized, multicenter phase 3 PETACC-2 trial datasetAnnett Maderer, Frederic Fiteni, Erik Tanis, et al.
World Journal of Gastroenterology|January 20, 2009
Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patientsMarkus Moehler, Martin-F Sprinzl, Murad Abdelfattah, et al.
JAMA Oncology|August 25, 2022
Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical TrialsHarry H Yoon, Zhaohui Jin, Oudom Kour, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|February 3, 2017
Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOGKozo Kataoka, Takahiro Kinoshita, Markus Moehler, et al.
Radiation Oncology (London, England)|March 3, 2024
Multicenter analysis on the value of standard (chemo)radiotherapy in elderly patients with locally advanced adenocarcinoma of the esophagus or gastroesophageal junctionTilman Bostel, Eirini Nikolaidou, Daniel Wollschläger, et al.
Pageof 22

Showing results (101-110 of 218) with videos related to

Sort By:
Pageof 22
Oncology Reports|November 8, 2006
Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced diseaseThomas Wehler, Felix Wolfert, Carl C Schimanski, et al.
BMC Cancer|January 13, 2019
Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker programMarkus Moehler, Annett Maderer, Anne Ehrlich, et al.
BMC Cancer|January 16, 2020
Young-onset gastric cancer and Epstein-Barr Virus (EBV) - a major player in the pathogenesis?Assaf Moore, Elad Hikri, Tal Goshen-Lago, et al.
International Journal of Colorectal Disease|September 18, 2012
Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapyThomas C Wehler, Swaantje Hamdi, Annett Maderer, et al.
BMC Cancer|February 12, 2013
Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junctionMarkus Moehler, Ines Gockel, Hans-Peter Roessler, et al.
Acta Oncologica (Stockholm, Sweden)|August 6, 2021
CXCR4 and hif-1α as prognostic molecular markers for stage 3 colon cancer patients: post hoc analysis of the randomized, multicenter phase 3 PETACC-2 trial datasetAnnett Maderer, Frederic Fiteni, Erik Tanis, et al.
World Journal of Gastroenterology|January 20, 2009
Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patientsMarkus Moehler, Martin-F Sprinzl, Murad Abdelfattah, et al.
JAMA Oncology|August 25, 2022
Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical TrialsHarry H Yoon, Zhaohui Jin, Oudom Kour, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|February 3, 2017
Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOGKozo Kataoka, Takahiro Kinoshita, Markus Moehler, et al.
Radiation Oncology (London, England)|March 3, 2024
Multicenter analysis on the value of standard (chemo)radiotherapy in elderly patients with locally advanced adenocarcinoma of the esophagus or gastroesophageal junctionTilman Bostel, Eirini Nikolaidou, Daniel Wollschläger, et al.
Pageof 22